Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells $186,866.40 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 55,615 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the transaction, the chief executive officer now directly owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Organogenesis Stock Up 0.6 %

Shares of ORGO stock opened at $3.57 on Wednesday. The stock’s fifty day moving average price is $3.45 and its 200 day moving average price is $3.01. Organogenesis Holdings Inc. has a 1-year low of $2.16 and a 1-year high of $4.70. The company has a market cap of $473.30 million, a price-to-earnings ratio of -59.50 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the previous year, the firm earned $0.02 earnings per share. On average, research analysts expect that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC grew its holdings in shares of Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after buying an additional 986,132 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Organogenesis by 19.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after acquiring an additional 333,123 shares during the period. Wealth Dimensions Group Ltd. lifted its position in Organogenesis by 435.9% during the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock worth $1,142,000 after acquiring an additional 331,840 shares during the period. Cubist Systematic Strategies LLC grew its stake in Organogenesis by 1,350.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock valued at $265,000 after purchasing an additional 88,175 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Organogenesis by 2.4% in the second quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after purchasing an additional 72,696 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.